RedHill Biopharma (RDHL) Current Leases (2019 - 2025)

RedHill Biopharma (RDHL) has 7 years of Current Leases data on file, last reported at $900000.0 in Q4 2025.

• Current Leases for Q4 2025 came in at $900000.0, up 154.96% year-over-year; the trailing twelve-month figure through Dec 2025 was $900000.0 (up 154.96% YoY), and the FY2025 annual result was $900000.0, up 154.96% from the prior year.
• Current Leases rose to $900000.0 in Q4 2025 per RDHL's latest filing, from $214000.0 in the prior quarter.
• Over five years, Current Leases peaked at $7.2 million in Q1 2022 and troughed at $214000.0 in Q2 2025.
• A 5-year average of $3.2 million and a median of $2.8 million in 2021 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2025: Current Leases slumped 88.86% in 2023, then surged 154.96% in 2025.
• A 5-year view of Current Leases shows it stood at $2.6 million in 2021, then jumped by 150.31% to $6.4 million in 2022, then tumbled by 88.86% to $718000.0 in 2023, then tumbled by 50.84% to $353000.0 in 2024, then surged by 154.96% to $900000.0 in 2025.
• Business Quant data shows RDHL's Current Leases at $900000.0 in Q4 2025, $214000.0 in Q2 2025, and $353000.0 in Q4 2024.